PolyTherics, MacroGenics extend deal to develop new antibody drug conjugates Pharmaceutical Business Review MacroGenics has two antibody technology platforms, which includes a Dual-Affinity Re-Targeting (DART) bi-specific platform, in which a single recombinant molecule is able to target two different antigens, and Fc-optimized antibodies with improved ... |
